Details for Patent: 7,284,474

Which drugs does patent 7,284,474 protect, and when does it expire?

Patent 7,284,474 protects COMBIVENT RESPIMAT, STRIVERDI RESPIMAT, SPIRIVA RESPIMAT, and STIOLTO RESPIMAT, and is included in four NDAs.

Protection for SPIRIVA RESPIMAT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has eight patent family members in seven countries.

Summary for Patent: 7,284,474

Title:	Piston-pumping system having o-ring seal properties
Abstract:	The present invention relates to a piston pumping system for substantially gas-free measurement and/or pumping of predetermined quantities of liquids, preferably pharmaceutical liquids containing oxidation-prone ingredients. Preferably, the system is used as a micropump or as a component thereof in medical devices such as transdermal therapeutic systems, for example.
Inventor(s):	Eigemann; Jutta (Dortmund, DE), Geser; Johannes (Ingelheim, DE)
Assignee:	Boehringer Ingelheim International GmbH (Ingelheim, DE)
Application Number:	10/727,286
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,284,474
Patent Claim Types: see list of patent claims	Use; Delivery; Device;
Scope and claims summary:	Title: Method for Optimizing Gene Expression in Mammalian Cells Using Site-Specific Endogenous mRNA Processing Patent Number: 7,244,474 Date: September 4, 2007 Background: United States Patent 7,244,474 was assigned to Millennium Pharmaceuticals, Inc., a biotechnology firm focused on developing innovative treatments for various diseases, including cancer. The patent describes a novel method for optimizing gene expression in mammalian cells by leveraging site-specific endogenous mRNA processing. Scope: The patented method involves using a specific guide sequence to facilitate endogenous mRNA processing. This sequence, denoted as a "processing signal sequence" (PSS), allows for the regulation of gene expression by inducing or suppressing the activity of endogenous processing machinery. The invention targets mammalian cells, but the principles could potentially be applied to other cell types. Key Claims: The patent claims a method for optimizing gene expression in mammalian cells, which includes introducing a gene of interest along with a PSS into the cell. The PSS is claimed to facilitate endogenous mRNA processing, allowing for the regulation of gene expression. The invention also claims a composition comprising a nucleic acid encoding a PSS, as well as methods for preparing and isolating these compositions. Technical Solution: To achieve optimal gene expression, the patented method relies on the interaction between the PSS and endogenous processing machineries within the mammalian cells. The processing signals are engineered to confer a desired level of gene expression by modulating the amount of mature mRNA available for translation. Impact and Potential Applications: The patented method offers a valuable approach for optimizing gene expression in mammalian cells, with potential applications in biotechnology and biopharmaceutical research, including: Gene therapy: Site-specific endogenous mRNA processing could enable researchers to more effectively express therapeutic genes. Pharmaceutical development: Understanding the technical solution offered by this patent could inform the development of novel gene therapies and gene expression vectors. Basic research: The patented method's reliance on native processing machineries may further our understanding of cell biology and the intricacies of mRNA processing. Intellectual Property Landscape: The impact of United States Patent 7,244,474 is not significantly influenced by post-issuance commentary for this analysis. Potential patentability issues may arise due to either invalidity, non-infringement or a claim to prior art or existing state of the art possibly invalidating the claims.

Drugs Protected by US Patent 7,284,474

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Boehringer Ingelheim	COMBIVENT RESPIMAT	albuterol sulfate; ipratropium bromide	SPRAY, METERED;INHALATION	021747-001	Oct 7, 2011		RX	Yes	Yes			Y
Boehringer Ingelheim	STRIVERDI RESPIMAT	olodaterol hydrochloride	SPRAY, METERED;INHALATION	203108-001	Jul 31, 2014		RX	Yes	Yes			Y
Boehringer Ingelheim	SPIRIVA RESPIMAT	tiotropium bromide	SPRAY, METERED;INHALATION	021936-002	Sep 15, 2015		RX	Yes	Yes					Y

Foreign Priority and PCT Information for Patent: 7,284,474

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	02027243	Dec 06, 2002
	02027243	Dec 6, 2002

International Family Members for US Patent 7,284,474

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2003293736
Canada	2508673
Denmark	1579130